CompletedNCT00835120
Pioglitazone added for depression in bipolarity and metabolic syndrome
About this title
Read the official source — NCT00835120Medication studyAges 18–70United States
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
- Listed locations
- ClevelandSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateMarch 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 34
- Sponsor
- University Hospitals Cleveland Medical Center
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT00835120
- Official title
Show the full official title
Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cleveland
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University Hospitals Cleveland Medical Center, a university.
Did this study involve medication?
Yes. The study involved medication, including Pioglitazone.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
